The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Most malignant cells displayed moderate to strong immunoreactivity in cytoplasm and nuclei. A majority of prostate, cervical and liver cancer were weakly stained or negative.
Cancer tissues displayed weak to moderate cytoplasmic staining with nuclear and membranous positivity in many cases. A single case of renal cancer and duct carcinoma of breast was strongly positive. Several cases of malignant lymphomas, stomach, pancreatic, skin and cervical cancers were negative.
Validation
One antibody yielding a staining pattern which is partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
The multi-targeting antibody yielding a staining pattern consistent with gene/protein characterization data for all of the genes
